Nautilus Biotechnology, INC 10-Q quarterly reports

Nautilus Biotechnology reported a net loss of $14.5 million for Q2 2026, a slight improvement from the prior year, while also announcing a strategic shift to prioritize proteoform development over its broadscale assay.

Nautilus Biotechnology reports a decrease in operating expenses for Q1 2026, driven by lower R&D and SG&A costs, while cash reserves remain sufficient for at least the next 12 months.

Nautilus Biotechnology, a development-stage proteomics company, reported reduced net losses and operating expenses for Q3 2025, while addressing a Nasdaq minimum bid price compliance issue.

Nautilus Biotechnology reported a reduced net loss in the second quarter of 2025, driven by cost optimization efforts, as it continues to advance its proteomics platform towards a late 2026 commercial launch while addressing a Nasdaq minimum bid price deficiency.

Nautilus Biotechnology reports a net loss for Q1 2025 while continuing to advance the development of its proteomics platform.

Nautilus Biotechnology's Q3 2024 report reveals a net loss of $16.4 million, with ongoing investments in research and development.

Nautilus Biotechnology, a development-stage life sciences company, reported a net loss of $36.7 million for the six months ended June 30, 2024, as it continues to focus on the development of its proteomics platform.

Nautilus Biotechnology's first quarter 2024 results show an increased net loss of $18.7 million, driven by higher operating expenses as the company continues to develop its proteomics platform.